|
|Section2= |Section3= }} 3-bromopyruvic acid, or its alkaline form, 3-bromopyruvate, are synthetic brominated derivatives of pyruvic acid. They are lactic acid and pyruvate analogs. The characteristics of 3-bromopyruvate ''in vitro'' and ''in vivo'' have been reported in the scientific literature since the 1940s. Because it is a highly reactive alkylating agent and it is inherently unstable, it had been described as a metabolic poison. == Research activity == In 1993 researchees at the Johns Hopkins School of Medicine reported that a pyruvate transporter system could be used to deliver 3-bromopyruvate inside trypanosomal cells where its primary target is glyceraldehyde-3-phosphate dehydrogenase, which is highly sensitive to inhibition by 3-bromopyruvate. A 2002 study suggested that intra-arterial delivery of bromopyruvic acid directly to the site of tumors in rabbits could represent a strategy for stopping the growth of liver cancer while minimizing toxic side-effects. An application for patent has been submitted.〔(Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production )〕 Research at Johns Hopkins has suggested that 3-bromopyruvate could be used to selectively kill cancer cells, while leaving normal cells intact. A Johns Hopkins press release dated October 14, 2004 stated that, "Building on their earlier work, Johns Hopkins researchers have discovered that an apparently nontoxic cellular "energy blocker" can eradicate large liver tumors grown in rats. In July 2013, the FDA accepted an IND application for the use of 3-bromopyruvate for a Phase I clinical trial in liver cancer. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Bromopyruvic acid」の詳細全文を読む スポンサード リンク
|